Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
vaccines
Biotech
YS Biopharma's rabies vaccine beats approved competitor in ph. 3
China’s YS Biopharma has a good feeling about a phase 3 trial of its investigational PIKA rabies vaccine based on an interim readout.
James Waldron
Apr 9, 2024 10:55am
Moderna touts 3 phase 1 data sets to bolster early vax work
Mar 27, 2024 3:21pm
Moderna's next-gen COVID vax surpasses approved version in ph. 3
Mar 26, 2024 10:55am
Bavarian Nordic halts cancer vaccine program
Feb 21, 2024 7:25am
Everest to continue mRNA ascent alone, ending Providence collab
Feb 20, 2024 8:19am
Valneva sells priority review voucher for $103M, R&D to benefit
Feb 5, 2024 9:15am